MR-guided focused ultrasound increases antibody delivery to nonenhancing high-grade glioma.
MRI
blood
brain barrier
focused ultrasound
high-grade glioma
vasculature permeability
Journal
Neuro-oncology advances
ISSN: 2632-2498
Titre abrégé: Neurooncol Adv
Pays: England
ID NLM: 101755003
Informations de publication
Date de publication:
Historique:
entrez:
10
7
2020
pubmed:
10
7
2020
medline:
10
7
2020
Statut:
epublish
Résumé
High-grade glioma (HGG) remains a recalcitrant clinical problem despite many decades of research. A major challenge in improving prognosis is the inability of current therapeutic strategies to address a clinically significant burden of infiltrating tumor cells that extend beyond the margins of the primary tumor mass. Such cells cannot be surgically excised nor efficiently targeted by radiation therapy. Therapeutic targeting of this tumor cell population is significantly hampered by the presence of an intact blood-brain barrier (BBB). In this study, we performed a preclinical investigation of the efficiency of MR-guided Focused Ultrasound (FUS) to temporarily disrupt the BBB to allow selective delivery of a tumor-targeting antibody to infiltrating tumor. Structural MRI, dynamic-contrast enhancement MRI, and histology were used to fully characterize the MR-enhancing properties of a patient-derived xenograft (PDX) orthotopic mouse model of HGG and to develop a reproducible, robust model of nonenhancing HGG. PET-CT imaging techniques were then used to evaluate the efficacy of FUS to increase The PDX mouse model of HGG has a significant tumor burden lying behind an intact BBB. Increased antibody uptake in nonenhancing tumor regions is directly proportional to the FUS-targeted volume. FUS locally increased antibody uptake in FUS-targeted regions of the tumor with an intact BBB, while leaving untargeted regions unaffected. FUS exposure successfully allowed temporary BBB disruption, localized to specifically targeted, nonenhancing, infiltrating tumor regions and delivery of a systemically administered antibody was significantly increased.
Sections du résumé
BACKGROUND
BACKGROUND
High-grade glioma (HGG) remains a recalcitrant clinical problem despite many decades of research. A major challenge in improving prognosis is the inability of current therapeutic strategies to address a clinically significant burden of infiltrating tumor cells that extend beyond the margins of the primary tumor mass. Such cells cannot be surgically excised nor efficiently targeted by radiation therapy. Therapeutic targeting of this tumor cell population is significantly hampered by the presence of an intact blood-brain barrier (BBB). In this study, we performed a preclinical investigation of the efficiency of MR-guided Focused Ultrasound (FUS) to temporarily disrupt the BBB to allow selective delivery of a tumor-targeting antibody to infiltrating tumor.
METHODS
METHODS
Structural MRI, dynamic-contrast enhancement MRI, and histology were used to fully characterize the MR-enhancing properties of a patient-derived xenograft (PDX) orthotopic mouse model of HGG and to develop a reproducible, robust model of nonenhancing HGG. PET-CT imaging techniques were then used to evaluate the efficacy of FUS to increase
RESULTS
RESULTS
The PDX mouse model of HGG has a significant tumor burden lying behind an intact BBB. Increased antibody uptake in nonenhancing tumor regions is directly proportional to the FUS-targeted volume. FUS locally increased antibody uptake in FUS-targeted regions of the tumor with an intact BBB, while leaving untargeted regions unaffected.
CONCLUSIONS
CONCLUSIONS
FUS exposure successfully allowed temporary BBB disruption, localized to specifically targeted, nonenhancing, infiltrating tumor regions and delivery of a systemically administered antibody was significantly increased.
Identifiants
pubmed: 32642689
doi: 10.1093/noajnl/vdaa030
pii: vdaa030
pmc: PMC7212871
doi:
Types de publication
Journal Article
Langues
eng
Pagination
vdaa030Informations de copyright
© The Author(s) 2020. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology.
Références
Biochem Soc Trans. 2014 Dec;42(6):1647-52
pubmed: 25399584
Proc Natl Acad Sci U S A. 2006 Aug 1;103(31):11719-23
pubmed: 16868082
J Transl Med. 2015;13:93
pubmed: 25784614
PLoS One. 2013;8(3):e58995
pubmed: 23527068
Front Cell Neurosci. 2014 Nov 03;8:362
pubmed: 25404894
Oncotarget. 2017 Oct 6;8(53):91779-91794
pubmed: 29207684
Neuroimage. 2012 Aug 15;62(2):782-90
pubmed: 21979382
Sci Rep. 2019 Mar 20;9(1):4902
pubmed: 30894629
J Vis Exp. 2015 Feb 12;(96):
pubmed: 25741890
Neurosci Biobehav Rev. 1996 Autumn;20(3):445-52
pubmed: 8880734
Sci Transl Med. 2016 Jun 15;8(343):343re2
pubmed: 27306666
Radiology. 2016 Oct;281(1):99-108
pubmed: 27192459
Biochem Biophys Res Commun. 2006 Feb 24;340(4):1085-90
pubmed: 16403441
Adv Drug Deliv Rev. 2018 Nov - Dec;136-137:49-61
pubmed: 30308226
PLoS One. 2010 May 11;5(5):e10549
pubmed: 20485502
Pharmaceutics. 2015 Aug 03;7(3):175-87
pubmed: 26247958
Annu Rev Med. 2009;60:417-30
pubmed: 19630579
J Control Release. 2012 Aug 20;162(1):134-42
pubmed: 22709590
Cancer Chemother Pharmacol. 2017 Dec;80(6):1209-1217
pubmed: 29075855
Cancer Cell. 2013 Feb 11;23(2):238-48
pubmed: 23410976
Front Cell Neurosci. 2014 Dec 12;8:418
pubmed: 25565956
Neurology. 2011 Feb 1;76(5):414-5
pubmed: 21282587
Nature. 2010 Dec 9;468(7325):829-33
pubmed: 21102433
J Neurosurg. 2016 Jun;124(6):1602-10
pubmed: 26566207
Mol Imaging. 2015;14:385-99
pubmed: 26218510
Neuroimage. 2019 Nov 15;202:116137
pubmed: 31473352
J Ultrasound Med. 2009 Jul;28(7):871-80
pubmed: 19546329
Proc Natl Acad Sci U S A. 2018 Sep 11;115(37):E8717-E8726
pubmed: 30150398
Int J Cancer. 2007 Aug 15;121(4):901-7
pubmed: 17437269
Theranostics. 2019 Aug 14;9(21):6284-6299
pubmed: 31534551
Proc Natl Acad Sci U S A. 2017 Jan 3;114(1):E75-E84
pubmed: 27994152
Neurology. 2018 Oct 2;91(14):e1355-e1359
pubmed: 30171077
J Control Release. 2016 Sep 28;238:281-288
pubmed: 27496633
J Control Release. 2017 Mar 28;250:77-85
pubmed: 27742444
J Neuroinflammation. 2019 Jul 25;16(1):155
pubmed: 31345243
Front Cell Neurosci. 2013 Apr 16;7:40
pubmed: 23596394
Transl Oncol. 2017 Aug;10(4):650-660
pubmed: 28668763
J Control Release. 2012 Nov 10;163(3):277-84
pubmed: 23000189
Biochem Biophys Res Commun. 2015 Dec 18;468(3):485-9
pubmed: 26116770
Proc Natl Acad Sci U S A. 2017 Aug 15;114(33):E6735-E6736
pubmed: 28798067
Proc Natl Acad Sci U S A. 2010 Aug 31;107(35):15553-8
pubmed: 20702765
Neurosurg Focus. 2018 Feb;44(2):E10
pubmed: 29385922
Neuroimage. 2011 Feb 1;54(3):2033-44
pubmed: 20851191
Cancer. 2013 Oct 1;119(19):3489-95
pubmed: 23868553
Neuroimage. 2006 Jul 1;31(3):1116-28
pubmed: 16545965
Neuro Oncol. 2018 Jan 22;20(2):184-191
pubmed: 29016900
PLoS One. 2008 May 14;3(5):e2175
pubmed: 18478109
Am J Pathol. 2012 Oct;181(4):1126-41
pubmed: 22858156
Sci Rep. 2019 Jun 25;9(1):9255
pubmed: 31239479